<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mechanisms of glomerular hyperfiltration in diabetes mellitus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mechanisms of glomerular hyperfiltration in diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mechanisms of glomerular hyperfiltration in diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H712765369"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A 25 to 50 percent elevation in the glomerular filtration rate (GFR) is seen early in the course in up to one-half of patients with type 1 diabetes mellitus [<a href="#rid1">1,2</a>], an abnormality that is exaggerated after ingestion of a protein load [<a href="#rid3">3</a>]. Glomerular hypertrophy and increased kidney size typically accompany the rise in GFR [<a href="#rid3">3</a>].</p><p>In addition to type 1 diabetes, hyperfiltration also occurs early in the course of type 2 diabetes [<a href="#rid4">4-6</a>]. In an original report of 110 newly diagnosed patients with type 2 diabetes mellitus, for example, the GFR was above 140 mL/min in 16 percent and more than two standard deviations above the mean of a control population in 45 percent [<a href="#rid5">5</a>]. The prevalence of hyperfiltration may be lower in the era of more aggressive glucose control. A later study of 93 newly diagnosed patients, for example, found that 17 percent had a GFR that was more than two standard deviations above the mean of a control population [<a href="#rid7">7</a>].</p><p>The degree of hyperfiltration and the course of the GFR in type 2 diabetes mellitus was evaluated in more detail in a study of 194 Pima Indians who had GFR measured using iothalamate clearance [<a href="#rid6">6</a>]. The following results were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>In 31 patients with a normal glucose tolerance test, the mean GFR was 123 mL/min.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 29 patients with impaired glucose tolerance, the mean GFR was 135 mL/min.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 30 patients with newly diagnosed type 2 disease, the mean GFR was 143 mL/min.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 70 patients with overt diabetes for more than five years and either normal albumin excretion or moderately increased albuminuria (formerly called "microalbuminuria"), the mean GFR was 153 mL/min; in 34 similar patients with overt proteinuria, the mean GFR was 124 mL/min.</p><p></p><p>After four years of follow-up, the GFR rose 14 percent in patients with impaired glucose tolerance, 18 percent in newly diagnosed patients, was stable in those with moderately increased albuminuria, and fell 35 percent in those with overt proteinuria. The rate of fall in GFR in the last group was 0.93 mL/min per month, a rate similar to that seen in type 2 diabetes with overt proteinuria.</p><p>These hemodynamic and structural changes may be important clinically because intraglomerular hypertension (which is responsible for part of the rise in GFR) and glomerular hypertrophy (which increases shear stress on the glomerular capillary wall) may play an important role in the development and progression of diabetic nephropathy [<a href="#rid8">8</a>]. </p><p>Although hyperfiltration is exacerbated by a dietary protein load [<a href="#rid3">3</a>], long-term trials in patients with obesity who had type 2 diabetes mellitus found that high-protein diets had little to no effect on kidney function [<a href="#rid1">1,9</a>]. (See  <a class="medical medical_review" href="/z/d/html/3103.html" rel="external">"Diabetic kidney disease: Pathogenesis and epidemiology"</a>.)</p><p>Measurement of GFR is usually required to detect hyperfiltration because estimation equations, such as the Modification of Diet in Renal Disease (MDRD) study equation, usually underestimate the true GFR when it is normal or above normal. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function"</a> and  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function", section on 'Measurement of GFR with plasma clearance'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM</span><span class="headingEndMark"> — </span>Studies in experimental animals indicate that dilatation of the afferent (precapillary) glomerular arteriole plays an important role in the hyperfiltration response, by raising both the intraglomerular pressure and renal blood flow [<a href="#rid2">2</a>]. Why these hemodynamic changes occur is not well understood, but the following factors appear to contribute.</p><p class="headingAnchor" id="H3"><span class="h2">Hormones</span><span class="headingEndMark"> — </span>A role for hormones is suggested by the ability of a chronic infusion of a somatostatin analogue (<a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a>) to partially reverse both the early hyperfiltration and the increase in kidney size in type 1 diabetic patients [<a href="#rid10">10</a>]. In this study, glucose control and plasma glucagon and growth hormone levels were unchanged. There was, however, a fall in the plasma concentration of insulin-like growth factor 1 (IGF1), which is produced, in part, within the kidney.</p><p>Although the pathogenetic role of IGF1 is unproven, it is of interest that infusion of this hormone in normal subjects can replicate the findings seen in diabetics: renal vasodilatation and an elevation in glomerular filtration rate (GFR) [<a href="#rid11">11</a>]. Similar hemodynamic changes plus kidney hypertrophy can be induced by IGF1 in experimental animals [<a href="#rid12">12</a>].</p><p>In addition to IGF1 and other hormones, atrial natriuretic peptide had been postulated to contribute to hyperfiltration, but this is unproven [<a href="#rid13">13,14</a>]. Volume expansion due to increased sodium reabsorption may trigger its secretion, which can result in dilation of the afferent arteriole. (See <a class="local">'Increased sodium reabsorption and tubuloglomerular feedback'</a> below.) </p><p>Increased nitric oxide and cyclooxygenase 2 (COX-2)-derived prostanoids have also been implicated in vasodilatation of the afferent arteriole [<a href="#rid15">15,16</a>]. Theoretically, glomerular hyperfiltration in the early stages of diabetes occurs mainly in response to signals passed from the tubule to the glomerulus. Taken together, these studies suggest that the renin-angiotensin-aldosterone axis, COX-2, and nitric oxide systems are involved in the regulation of glomerular arteriolar tone in diabetes [<a href="#rid17">17</a>]<em>.</em></p><p>Sex hormones may affect the degree of glomerular hyperfiltration. In one study, females had a reduction in renal plasma flow and renal blood flow and decreased renal vascular resistance in response to hyperglycemia, but no change was detected in males [<a href="#rid18">18</a>]. With angiotensin-converting enzyme (ACE) inhibition, both sexes had a reduction in arterial pressure, but only females exhibited reduction in GFR.</p><p class="headingAnchor" id="H4"><span class="h2">Sorbitol</span><span class="headingEndMark"> — </span>Several other factors directly related to hyperglycemia also may be important, including the intracellular accumulation of <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a> and the formation of glycosylated proteins. The enzyme aldose reductase converts intracellular glucose to sorbitol, which then accumulates within the cells. Studies in hyperfiltering humans with type 1 diabetes have shown that the chronic administration of an aldose reductase inhibitor (tolrestat) lowers the GFR toward normal. In one study of patients who also had moderately increased albuminuria (formerly called "microalbuminuria"), for example, the GFR fell from 156 to 124 mL/min and albumin excretion fell from 197 to 158 mg/day after six months of tolrestat [<a href="#rid19">19</a>]. The possible efficacy of this regimen to prevent diabetic nephropathy remains to be determined.</p><p class="headingAnchor" id="H5"><span class="h2">Glycation products</span><span class="headingEndMark"> — </span>In chronic hyperglycemia, some of the excess circulating glucose combines with free amino acids on circulating or tissue proteins. This nonenzymatic process initially forms reversible early glycation products and later irreversible advanced glycation end products, which may accumulate in tissues and contribute to the kidney and microvascular complications of diabetes  (<a class="graphic graphic_figure graphicRef80716" href="/z/d/graphic/80716.html" rel="external">figure 1</a>) [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/3103.html" rel="external">"Diabetic kidney disease: Pathogenesis and epidemiology"</a>.)</p><p>In normal rats, the infusion of early glycation products to achieve plasma concentrations similar to that seen in diabetic rats can induce the increases in renal plasma flow, GFR, and intraglomerular pressure typical of untreated diabetes [<a href="#rid21">21</a>]. The applicability of this observation to humans is at present unproven.</p><p class="headingAnchor" id="H6"><span class="h2">Increased sodium reabsorption and tubuloglomerular feedback</span><span class="headingEndMark"> — </span>Enhanced tubular sodium reabsorption, due to augmented sodium-glucose cotransport, leading to extracellular fluid volume expansion may be an additional factor contributing to the rise in GFR [<a href="#rid2">2,22</a>]. Hyperinsulinemia (due to subcutaneous administration) and mild hyperglycemia can also stimulate sodium reabsorption, the latter via increased sodium-glucose cotransport in the proximal tubule [<a href="#rid23">23,24</a>]. The rise in proximal reabsorption initially decreases distal fluid delivery that, by activating the tubuloglomerular feedback mechanism in the macula densa, can then raise the GFR via dilatation of the afferent arteriole [<a href="#rid23">23</a>]. Additional evidence to support this concept comes from studies using blockers of the sodium-glucose transporters in both patients with type 1 and type 2 diabetes [<a href="#rid25">25-27</a>]. </p><p>High concentrations of glucose in the glomerular filtrate drive greater sodium-coupled glucose reabsorption through sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule. Reduced sodium chloride delivery to the macula densa inhibits adenosine triphosphate conversion into adenosine, leading to lower levels of this vasoconstrictor and a reduction in afferent arteriolar tone. This results in increased blood flow and raises intraglomerular pressure [<a href="#rid28">28</a>]<em>. </em></p><p>SGLT1 transporters may also play a role in hyperfiltration [<a href="#rid29">29</a>]. Increased luminal glucose at the macula densa is sensed by SGLT1, consequently upregulating nitric oxide synthase 1 expression and activity and thereby reducing vasoconstrictor tone. </p><p>Thus, both SGLT2 and SGLT1 pathways may additively promote glomerular hyperfiltration in diabetes.</p><p>The hyperfiltration in this setting is appropriate from a kidney viewpoint since it counteracts the effect of enhanced proximal reabsorption, thereby returning distal sodium and water delivery toward normal and preventing excess fluid retention.</p><p class="headingAnchor" id="H21341632"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Elevations in the glomerular filtration rate (GFR) are seen early in the course in many patients with diabetes mellitus. Glomerular hypertrophy and increased kidney size typically accompany the rise in GFR. Intraglomerular hypertension and glomerular hypertrophy may play an important role in the development and progression of diabetic nephropathy. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/z/d/html/3103.html" rel="external">"Diabetic kidney disease: Pathogenesis and epidemiology"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dilatation of the afferent (precapillary) glomerular arteriole plays an important role in hyperfiltration. Factors that may contribute to afferent arteriole dilatation include insulin-like growth factor 1 (IGF1), atrial natriuretic peptide, sex hormones, intracellular <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a>, early glycation products, and enhanced tubular sodium reabsorption in the proximal tubule. (See <a class="local">'Mechanism'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cortinovis M, Perico N, Ruggenenti P, et al. Glomerular hyperfiltration. Nat Rev Nephrol 2022; 18:435.</a></li><li><a class="nounderline abstract_t">Bank N. Mechanisms of diabetic hyperfiltration. Kidney Int 1991; 40:792.</a></li><li><a class="nounderline abstract_t">Tuttle KR, Bruton JL, Perusek MC, et al. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 1991; 324:1626.</a></li><li><a class="nounderline abstract_t">Tonneijck L, Muskiet MH, Smits MM, et al. Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. J Am Soc Nephrol 2017; 28:1023.</a></li><li><a class="nounderline abstract_t">Vora JP, Dolben J, Dean JD, et al. Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int 1992; 41:829.</a></li><li><a class="nounderline abstract_t">Nelson RG, Bennett PH, Beck GJ, et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996; 335:1636.</a></li><li><a class="nounderline abstract_t">Jin Y, Moriya T, Tanaka K, et al. Glomerular hyperfiltration in non-proteinuric and non-hypertensive Japanese type 2 diabetic patients. Diabetes Res Clin Pract 2006; 71:264.</a></li><li><a class="nounderline abstract_t">Bakris GL, Slataper R, Vicknair N, Sadler R. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications 1994; 8:2.</a></li><li><a class="nounderline abstract_t">Tay J, Thompson CH, Luscombe-Marsh ND, et al. Long-Term Effects of a Very Low Carbohydrate Compared With a High Carbohydrate Diet on Renal Function in Individuals With Type 2 Diabetes: A Randomized Trial. Medicine (Baltimore) 2015; 94:e2181.</a></li><li><a class="nounderline abstract_t">Serri O, Beauregard H, Brazeau P, et al. Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. JAMA 1991; 265:888.</a></li><li><a class="nounderline abstract_t">Hirschberg R, Brunori G, Kopple JD, Guler HP. Effects of insulin-like growth factor I on renal function in normal men. Kidney Int 1993; 43:387.</a></li><li><a class="nounderline abstract_t">Hirschberg R, Kopple JD. The growth hormone-insulin-like growth factor I axis and renal glomerular function. J Am Soc Nephrol 1992; 2:1417.</a></li><li><a class="nounderline abstract_t">Anderson S, Vora JP. Current concepts of renal hemodynamics in diabetes. J Diabetes Complications 1995; 9:304.</a></li><li><a class="nounderline abstract_t">Vervoort G, Veldman B, Berden JH, et al. Glomerular hyperfiltration in type 1 diabetes mellitus results from primary changes in proximal tubular sodium handling without changes in volume expansion. Eur J Clin Invest 2005; 35:330.</a></li><li><a class="nounderline abstract_t">Cherney DZ, Miller JA, Scholey JW, et al. Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes. Diabetes Care 2010; 33:1344.</a></li><li><a class="nounderline abstract_t">Chiarelli F, Cipollone F, Romano F, et al. Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration. Diabetes 2000; 49:1258.</a></li><li><a class="nounderline abstract_t">Sasson AN, Cherney DZ. Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes 2012; 3:1.</a></li><li><a class="nounderline abstract_t">Cherney DZ, Sochett EB, Miller JA. Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes. Kidney Int 2005; 68:1722.</a></li><li><a class="nounderline abstract_t">Passariello N, Sepe J, Marrazzo G, et al. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care 1993; 16:789.</a></li><li><a class="nounderline abstract_t">Vlassara H. Protein glycation in the kidney: role in diabetes and aging. Kidney Int 1996; 49:1795.</a></li><li><a class="nounderline abstract_t">Sabbatini M, Sansone G, Uccello F, et al. Early glycosylation products induce glomerular hyperfiltration in normal rats. Kidney Int 1992; 42:875.</a></li><li><a class="nounderline abstract_t">Vallon V, Blantz RC, Thomson S. Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol 2003; 14:530.</a></li><li><a class="nounderline abstract_t">Hannedouche TP, Delgado AG, Gnionsahe DA, et al. Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes. Kidney Int 1990; 37:1126.</a></li><li><a class="nounderline abstract_t">Vallon V, Richter K, Blantz RC, et al. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 1999; 10:2569.</a></li><li><a class="nounderline abstract_t">Skrtić M, Yang GK, Perkins BA, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014; 57:2599.</a></li><li><a class="nounderline abstract_t">Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129:587.</a></li><li><a class="nounderline abstract_t">Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab 2014; 5:53.</a></li><li><a class="nounderline abstract_t">Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol 2020; 16:317.</a></li><li><a class="nounderline abstract_t">Zhang J, Wei J, Jiang S, et al. Macula Densa SGLT1-NOS1-Tubuloglomerular Feedback Pathway, a New Mechanism for Glomerular Hyperfiltration during Hyperglycemia. J Am Soc Nephrol 2019; 30:578.</a></li></ol></div><div id="topicVersionRevision">Topic 3064 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35365815" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Glomerular hyperfiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1745032" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mechanisms of diabetic hyperfiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2030719" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28143897" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1513105" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8929360" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16125272" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Glomerular hyperfiltration in non-proteinuric and non-hypertensive Japanese type 2 diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8167383" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26632754" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Long-Term Effects of a Very Low Carbohydrate Compared With a High Carbohydrate Diet on Renal Function in Individuals With Type 2 Diabetes: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1992187" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8441234" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effects of insulin-like growth factor I on renal function in normal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1385734" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The growth hormone-insulin-like growth factor I axis and renal glomerular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8573753" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Current concepts of renal hemodynamics in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860045" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Glomerular hyperfiltration in type 1 diabetes mellitus results from primary changes in proximal tubular sodium handling without changes in volume expansion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20332349" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10909986" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22253940" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Renal hyperfiltration related to diabetes mellitus and obesity in human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16164648" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8495620" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8743500" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Protein glycation in the kidney: role in diabetes and aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1453582" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Early glycosylation products induce glomerular hyperfiltration in normal rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12538755" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2188030" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589696" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25280671" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24334175" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25126408" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Renal effects of dapagliflozin in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32152499" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The tubular hypothesis of nephron filtration and diabetic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30867247" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Macula Densa SGLT1-NOS1-Tubuloglomerular Feedback Pathway, a New Mechanism for Glomerular Hyperfiltration during Hyperglycemia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
